Edgewise Therapeutics (EWTX) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 161.4% versus a gain of 9.4%. Over five years, MIRM leads with a +371.0% price change compared with +123.1% for EWTX. Mirum Pharmaceuticals is the larger company by market cap ($5.26 billion vs $4.20 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | MIRM |
|---|---|---|
| Share price | $38.65 | $81.01 |
| Market cap | $4.20B | $5.26B |
| 1-day change | -2.34% | +0.46% |
| YTD return | +59.46% | +2.09% |
| 1-year return | +161.36% | +9.36% |
| 5-year return | +123.06% | +371.03% |
| EPS (TTM) | $-1.86 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | $-167.79M | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $48.51 | $130.00 |
| 52-week low | $14.25 | $63.23 |
| Distance from 52-week high | -20.34% | -37.68% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.16% | +79.97% |
| Average volume | 1.35M | 698.74K |
| Shares outstanding | 108.60M | 64.93M |
| Employees | 127 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed MIRM by 152.0 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
EWTX vs MIRM FAQ
Which is bigger, Edgewise Therapeutics or Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.26B compared with $4.20B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, EWTX or MIRM?
EWTX returned +161.36% over the past 12 months, compared with +9.36% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.